Kazia up on promising interim data from brain tumor study

Kazia Therapeutics

05/08/2022 13:59

** U.S.-listed shares of Australia's Kazia Therapeutics
 KZIA.O  rise 20.9% to $2.14 premarket
    ** Co reports promising interim data from an ongoing
early-stage trial testing lead drug candidate paxalisib in
combination with radiotherapy for treatment of brain metastases
 urn:newsml:reuters.com:*:nFWN2ZH8AK
    ** Brain metastases occur when cancer cells spread from
their original site to brain
    ** All nine evaluable patients experienced complete or
partial response, representing an overall response rate of 100%
- KZIA
    ** Stock is down ~79% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))